Almirall, S.A. Stock price

Equities

ALM

ES0157097017

Pharmaceuticals

Delayed BME 12:35:12 2024-03-28 pm EDT 5-day change 1st Jan Change
8.265 EUR +0.61% Intraday chart for Almirall, S.A. +3.05% -1.90%
Sales 2024 * 972M 1.05B Sales 2025 * 1.07B 1.15B Capitalization 1.73B 1.86B
Net income 2024 * 25M 26.94M Net income 2025 * 61M 65.73M EV / Sales 2024 * 1.68 x
Net cash position 2024 * 94.21M 102M Net cash position 2025 * 134M 145M EV / Sales 2025 * 1.49 x
P/E ratio 2024 *
80.4 x
P/E ratio 2025 *
29.1 x
Employees 1,904
Yield 2024 *
2.26%
Yield 2025 *
2.29%
Free-Float 34.78%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.61%
1 week+3.05%
Current month+4.36%
1 month+1.35%
3 months-2.71%
6 months-13.23%
Current year-1.90%
More quotes
1 week
7.97
Extreme 7.97
8.30
1 month
7.85
Extreme 7.85
8.30
Current year
7.85
Extreme 7.85
9.30
1 year
7.16
Extreme 7.16
10.08
3 years
7.16
Extreme 7.16
15.35
5 years
7.16
Extreme 7.16
18.50
10 years
7.16
Extreme 7.16
19.36
More quotes
Managers TitleAgeSince
Chief Executive Officer - 14-07-24
Director of Finance/CFO 54 19-11-10
Chief Tech/Sci/R&D Officer - 21-07-06
Members of the board TitleAgeSince
Director/Board Member 81 07-05-28
Director/Board Member - 15-12-31
Director/Board Member 65 20-06-30
More insiders
Date Price Change Volume
24-03-28 8.265 +0.61% 196,575
24-03-27 8.215 +0.80% 228,254
24-03-26 8.15 +1.31% 151,121
24-03-25 8.045 +0.19% 147,032
24-03-22 8.03 +0.12% 189,390

Delayed Quote BME, March 28, 2024 at 12:35 pm EDT

More quotes
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
8.265 EUR
Average target price
11.28 EUR
Spread / Average Target
+36.50%
Consensus
  1. Stock
  2. Equities
  3. Stock Almirall, S.A. - BME